Corbus pharmaceuticals holdings, inc. (CRBP)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14
Cash flows from operating activities:
Net loss

-71,453

-55,672

-32,421

-19,998

-8,850

-2,540

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation expense

11,981

7,609

5,694

3,163

1,153

193

Depreciation and amortization

739

493

255

87

43

-

Deferred rent

-

422

-

-

-

-

Foreign currency exchange gain (loss), net

-

-

-

-

-

4

Loss on foreign exchange

45

70

-8

14

-1

-

Operating lease right of use asset amortization

490

-

-

-

-

-

Deferred rent

-

-

913

75

0

-

Depreciation

-

-

-

-

-

10

Gain on settlement of notes payable, accrued interest and accounts payable

-

-

-

-

-

145

Changes in fair value of derivative warrant liability

-

-

-

-

-

28

Forgiveness of interest on notes payable

-

-

-

-

-

7

Non-cash interest expense

-

-

-

-

-

29

Changes in operating assets and liabilities:
Decrease in customer receivable

-5,000

-12,500

-1,000

1,000

0

-

Increase in prepaid expenses and other current assets

-

-

-

553

105

-

Increase in restricted cash

-

-

-

-

-

13

Decrease in prepaid expenses and other current assets

1,233

-281

1,877

-

-

268

Increase in contract asset

-2,681

-

-

-

-

-

Decrease in other assets

41

3

-

-

-

-

Increase in other assets

-

-

40

0

0

-

(Decrease) increase in accounts payable

4,366

3,904

-885

1,890

972

170

Increase in accrued expenses

12,555

5,113

1,514

2,660

312

186

Increase in deferred revenue

-6,462

-4,787

-

88

1,851

-

Decrease in deferred revenue

-

-

-1,940

-

-

-

Decrease in operating lease liabilities

971

-

-

-

-

-

Net cash (used in) provided by operating activities

-45,720

-30,067

-27,796

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-13,571

-4,624

-2,361

Purchases of property and equipment

2,742

2,300

707

353

114

64

Net cash used in investing activities

-2,742

-2,300

-707

-

-

-

Cash flows from financing activities:
Net cash used in investing activities

-

-

-

-353

-114

-64

Proceeds from issuance of notes payable

963

491

415

348

207

192

Principal payments on notes payable

605

430

354

239

190

247

Proceeds from issuance of common stock

40,677

12,052

78,891

16,699

11,328

10,305

Issuance costs paid for common stock financings

2,571

690

2,940

63

509

1,865

Principal payments under capital lease obligation

0

4

3

3

0

-

Net cash provided by financing activities

38,463

11,419

76,008

-

-

-

Net increase in cash and cash equivalents

-9,999

-20,948

47,504

-

-

-

Net cash provided by financing activities

-

-

-

16,741

10,837

8,385

Net increase in cash, cash equivalents, and restricted cash

-

-

-

2,817

6,098

-

Net increase in cash and cash equivalents

-

-

-

-

-

5,959

Supplemental disclosure of cash flow information and non-cash transactions:
Cash paid during the period for interest

29

10

12

5

0

-

Fair value of warrant issued in connection with Investment Agreement

-

6,215

-

-

-

-

Assets acquired under capital lease obligation

-

-

-

11

0

-

Purchases of property and equipment included in accounts payable or accrued expenses

376

1

579

34

0

-

Right of use assets obtained in exchange for lease obligation upon adoption of ASU 2016-02, net of deferred rent

2,399

-

-

-

-

-

Right of use assets obtained in exchange for lease obligation upon entry into lease agreements

3,909

-

-

-

-

-

Write off of fully amortized leasehold improvements

-

191

-

-

-

-

Unpaid stock issuance costs

-

-

225

196

0

-

Conversion of notes payable, accrued interest and accounts payable into common stock and a warrant

-

-

-

-

-

396

Reclassification of derivative warrant liability to equity

-

-

-

-

-

48